Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Consensus Nomenclature For CD8+ T Cell Phenotypes In Cancer

L. Apetoh, M. Smyth, C. Drake, Jean-Pierre Abastado, R. Apte, Maha Ayyoub, J. Blay, M. Bonneville, L. Butterfield, A. Caignard, C. Castelli, F. Cavallo, E. Celis, L. Chen, M. Colombo, B. Comin-Anduix, G. Coukos, M. Dhodapkar, G. Dranoff, I. Frazer, Wolf-Hervé Fridman, D. Gabrilovich, E. Gilboa, S. Gnjatic, D. Jaeger, P. Kalinski, H. Kaufman, R. Kiessling, J. Kirkwood, A. Knuth, R. Liblau, M. Lotze, E. Lugli, F. Marincola, I. Melero, C. Melief, T. Mempel, E. Mittendorf, Kunle Odun, W. Overwijk, A. Palucka, G. Parmiani, A. Ribas, P. Romero, R. Schreiber, G. Schuler, P. Srivastava, E. Tartour, D. Valmori, S. H. van der Burg, P. van der Bruggen, B. J. Van den Eynde, E. Wang, W. Zou, T. Whiteside, D. Speiser, D. Pardoll, N. Restifo, A. Anderson
Published 2015 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.
This paper references
Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?
F. Martin (2012)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
S. Blackburn (2009)
KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells.
S. Henson (2009)
Phenotypic T Cell Exhaustion in a Murine Model of Bacterial Infection in the Setting of Pre-Existing Malignancy
R. Mittal (2014)
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
J. Fourcade (2012)
Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure
S. Abouzahr (2006)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel (2007)
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.
B. Bréart (2008)
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P Dunn (2002)
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.
K. T. Brunner (1968)
11-color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity
S. Rosa (2001)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
L. Gattinoni (2005)
Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells
C. Pasare (2003)
, Costes A , Molidor R , et al . Effector memory T cells , early metastasis , and survival in colorectal cancer
F Sanchez-‐Cabo
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1
J. Fourcade (2009)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
S. Ladoire (2011)
, et al . Ex vivo identification , isolation and analysis of tumor -­‐ cytolytic T cells
V Rubio (2003)
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
T. Ratliff (1993)
Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
A. Jazirehi (2012)
The wolf in sheep's clothing: the role of interleukin-­‐6 in immunity, inflammation and cancer. Trends in molecular medicine
WE Naugler (2008)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.
N. Cieri (2013)
The who's who of T‐cell differentiation: Human memory T‐cell subsets
Y. Mahnke (2013)
Controversies on the role of Th17 in cancer: a TGF-­‐beta-­‐ dependent immunosuppressive activity? Trends in molecular medicine
F Martin (2012)
Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation
G. Beatty (2009)
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells
V. Rubio (2003)
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.
S. Street (2001)
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival
V. Koelzer (2014)
Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
R. Remark (2013)
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits CD8+ T cell memory formation
Y. Ji (2011)
Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection
E. Nakayama (1985)
A human memory T-cell subset with stem cell-like properties
L. Gattinoni (2011)
Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors
S. van Duikeren (2012)
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.
Willscott E. Naugler (2008)
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
C. Uyttenhove (1983)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V. Shankaran (2001)
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ
S. Street (2002)
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
Lukas Baitsch (2011)
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
O. Nakano (2001)
CD8+ T cell effector mechanisms in resistance to infection.
J. Harty (2000)
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.
Zhi-Zhang Yang (2012)
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
S. Schoenberger (1998)
A family of serine esterases in lytic granules of cytolytic T lymphocytes
D. Masson (1987)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E. Bettelli (2006)
Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer
A. Schietinger (2013)
Granzymes A and B are targeted to the lytic granules of lymphocytes by the mannose-6-phosphate receptor
G. Griffiths (1993)
The Interleukin-8 Pathway in Cancer
D. Waugh (2008)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Qing Zhou (2011)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
E. Sato (2005)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.
Y. Lee (2009)
T-helper-1-cell cytokines drive cancer into senescence
H. Braumüller (2013)
Cytotoxic T lymphocytes: all roads lead to death
M. Barry (2002)
Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression
C. Nunes (2011)
Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1).
D. Voehringer (2002)
Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy.
T. Takeshima (2010)
Serine esterase in cytolytic T lymphocytes
M. Pasternack (1986)
Plasmacytoid dendritic cells induce CD8C regulatory T cells in human ovarian carcinoma
S Wei (2005)
Bystander elimination of antigen loss variants in established tumors
M. Spiotto (2004)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
S. Mattarollo (2011)
Moving T memory stem cells to the clinic.
L. Gattinoni (2013)
Tumor-infiltrating CD8C lymphocytes predict clinical outcome in breast cancer
SM Mahmoud (2011)
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies.
L. Apetoh (2011)
T cells after allogeneic stem cell transplantation
Four faces of cellular senescence. The Journal of cell biology
F Rodier (2011)
Proteasome inhibition blocks NF-­‐kappaB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-­‐engineered CTLs. Molecular cancer therapeutics
AR Jazirehi (2012)
, Morgan KM , Vera E , et al . p 53 isoforms regulate aging -­‐ and tumor -­‐ associated replicative senescence in T lymphocytes
C Pasare (2013)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
A. Gros (2014)
Expansion of a CD8(C)PD-1(C) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression
C Nunes (2012)
Repression of the DNA-­‐binding inhibitor Id3 by Blimp-­‐1 limits the formation of memory CD8+ T cells
Y Ji (2011)
Cytokine patterns in patients with cancer: a systematic review.
B. Lippitz (2013)
Vonderheide RH. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8C
G L Beatty
Fas ligand–mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas
Shoukat Afshar-Sterle (2014)
Cancer immunotherapy by dendritic cells.
C. J. Melief (2008)
Anti‐tumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases
I. Gresser (1990)
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
T. Curiel (2003)
Effector memory T cells, early metastasis, and survival in colorectal cancer.
F. Pagès (2005)
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype
Joachim R. Göthert (2013)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
Daniel T Utzschneider (2013)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F. Ghiringhelli (2009)
T cell exhaustion
E. Wherry (2011)
Fuertes Marraco SA. Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T cells
A Legat (2013)
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Z. Qin (2003)
Actions of TNF and INF-γ on Angiogenesis In Vitro
N. Sato (1990)
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
A. Seo (2013)
Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin
E. Pearce (2003)
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
C. Badoual (2013)
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
J. Galon (2014)
Superior T memory stem cell persistence supports long-lived T cell memory.
E. Lugli (2013)
Intraepithelial CD8C tumor-infiltrating lymphocytes and a high CD8C/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato (2005)
Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion.
C. Montes (2008)
Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells
A. Legat (2013)
Cytolytic T cell granules. Isolation, structural, biochemical, and functional characterization
E. Podack (1984)
Four faces of cellular senescence
F. Rodier (2011)
Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin1
N. Seki (2002)
Actions of TNF and IFN-gamma on angiogenesis in vitro.
N. Sato (1990)
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
S. Mahmoud (2011)
A human memory T cell subset with stem cell-like e998538-9 OncoImmunology properties
L Gattinoni (2011)
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
J. Fourcade (2014)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
J. Fourcade (2010)
The Fas/Fas Ligand Pathway Is Important for Optimal Tumor Regression in a Mouse Model of CTL Adoptive Immunotherapy of Experimental CMS4 Lung Metastases
S. Caldwell (2003)
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes.
A. M. Mondal (2013)
The CD8+ granzyme B+ T‐cell subset in peripheral blood from healthy individuals contains activated and apoptosis‐prone cells
Wever (1998)
CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
R. Wang (2008)
pression of lymphoma and epithelial malignancies effected by interferon gamma
SE Street (2002)
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
A. Boissonnas (2007)
T cell anergy.
R. Schwartz (1993)
The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets
Cliff Y Yang (2011)
Antigen specific killing assay using CFSE labeled target cells.
M. Durward (2010)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael (2013)
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8C T cells
Y Ji (2011)
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
M. Smyth (2000)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
L. Zhang (2003)
Paths to stemness: building the ultimate antitumour T cell
L. Gattinoni (2012)
Hack CE, ten Berge IJ. The CD8C granzyme BC T-cell subset in peripheral blood from healthy individuals contains activated and apoptosis-prone cells
P C Wever (1998)
Tumour-infiltrating CD8C lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
AN Seo (2013)
Coregulation of CD8C T cell exhaustion by multiple inhibitory receptors during chronic viral infection
SD Blackburn (2009)
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
S. Wei (2005)
A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells
Z. Qin (2003)

This paper is referenced by
Danger signals: Chemotherapy enhancers?
Thaiz Rivera Vargas (2017)
Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer
Liusheng Peng (2016)
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
J. Boustani (2019)
Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
T. Gargett (2019)
Total tumor RNA pulsed dendritic cells plus adoptive transfer of ex-vivo enriched autologous T-lymphocytes in the treatment of children with primary brain tumors
S. Gururangan (2018)
Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues
Ravikumar Muthuswamy (2017)
Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans
A. Przybyla (2018)
Emerging Opportunities and Challenges in Cancer Immunotherapy
T. Whiteside (2016)
Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells
Aurélie Hanoteau (2017)
Proliferative tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells
Zinaida Good (2019)
Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice.
S. Chen (2016)
Tim-3 - Biomarqueur et cible thérapeutique en cancérologie
C. Granier (2018)
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
M. Dosset (2018)
Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
C. Catania (2016)
Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
Rohan Sardana (2020)
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck (2017)
Functional Genome Profiling to Understand Cancer Immune Responsiveness.
E. Wang (2020)
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
L. Festino (2016)
Mapping the Immune Landscape of Clear Cell Renal Cell Carcinoma by Single-Cell RNA-seq
Ajaykumar Vishwakarma (2019)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer
Liusheng Peng (2017)
Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Eun-Ah Bae (2018)
Repurposing the yellow fever vaccine for intratumoral immunotherapy
M. A. Aznar (2019)
Gender differences in cholinergic and dopaminergic deficits in Parkinson disease
V. Kotagal (2013)
Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Ashley R Orillion (2018)
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
K. Pilipów (2015)
Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer1
Tao Jiang (2017)
The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features
M. Ochi (2018)
[Comparison of T cell response in the tumor milieu of patients with HPV+ and HPV- head and neck cancer].
T. Bastian (2020)
PD-1 Blockade Expands Intratumoral Memory T Cells
A. Ribas (2016)
Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia
Nadja Hilger (2018)
Tumor‐infiltrating CD8+ T‐cell density is an independent prognostic marker for oral squamous cell carcinoma
S. Shimizu (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar